Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX-4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer

  • Haghighi, Shirin (Department of Oncology, Gastroenterology and Liver Disease Research Center) ;
  • Kasbkar, Hadi (School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Esmaeilpour, Keihan (School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Yasaei, Mehrdad (School of Medicine, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.07.01


Background: Gastric cancer is considered the fourth most common cancer and second most common cause of cancer-related mortalities worldwide. Gastric cancer develops more frequently among elderly. The oxaliplatin/5FU/leucovorin (FOLFOX) regimen has shown a notable activity against gastric cancer. Aim: To evaluate the responses and complications of FOLFOX-4 regimen as first line chemotherapy in elderly patients with advanced gastric cancer. Materials and Methods: From October 2014 to November 2015, a total of 21 patients with metastatic or local AGC (advanced gastric cancer) were analyzed. All patients were administered a FOLFOX-4 regimen consisting of a 2h infusion of oxaliplatin $85mg/m^2$ (day 1), continuous infusion of $1000mg/m^2$ 5-Fu in 24h., and leucovorin $200mg/m^2$ in 2h infusion as a first-line chemotherapy. Results: A total of 18 patients were assessable for efficacy and toxicity. One of 18 patients achieved a complete response, and 12 had partial responses, giving an overall response rate of 72.6%. Three (16%) patients demonstrated stable disease and 2 (12%) progression. The median progression free survival was 7.3 months, and the median overall survival was 11.9 months. One patient had grade 3 neuropathy. No other grade 3 or 4 NCI-CTC were seen. Conclusions: The FOLFOX-4 regimen used in our study was both active and acceptable for AGC in elderly patients as neoadjuvant and main therapy.


  1. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al (2004). Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol, 22, 658-63.
  2. Brenner H, Rothenbacher D, Arndt V (2009). Epidemiology of stomach cancer. Methods Mol Biol, 472, 467-77.
  3. Catalano V, Bisonni R, Graziano F, et al (2013). A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer, 16, 411-9.
  4. Cavanna L, Artioli F, Codignola C, et al (2006). Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol, 29, 371-5.
  5. Chen W, Shen J, Pan T, et al (2014). FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med, 7, 461-67.
  6. Cho YH, Kim SY, Hong Lee M, et al (2012). Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. Gastric Cancer, 15, 389-95.
  7. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer'. World J Gastroenterol, 12, 354-62.
  8. De Vita F, Orditura M, Matano E, et al (2005). A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer, 92, 1644-9.
  9. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.
  10. Hacibekiroglu I, Kodaz H, Erdogan B, et al (2015). Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status. Asian Pac J Cancer Prev, 16, 2355-9.
  11. Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.BMC Cancer, 8, 148.
  12. Kim HS, Kim JH, Kim HJ, et al (2012). Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as firstline chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett, 3, 425-28.
  13. Lee HH, Hur H, Kim SH, et al (2010). Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat, 42, 18-23.
  14. Li ZY, Koh CE, Bu ZD, et al (2012). Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol, 105, 793-9.
  15. Louvet C, Andre T, Tigaud JM, et al (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20, 4543-8.
  16. Luo HY, Xu RH, Zhang L, et al (2008). A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cance. Chemotherapy, 54, 228-35.
  17. Mohammad HA, Magdy FM, Mahmoud OM (2011). FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study. Indian J Cancer, 48, 460-5.
  18. Nardi M, Azzarello D, Maisano R, et al (2007). FOLFOX-4 regimen as fist-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. J Chemother, 19, 85-9.
  19. Oh SY, Kwon HC, Seo BG, et al (2007). A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol, 46, 336-41.
  20. Yeh YS, Tsai HL, Ma CJ, et al (2012). A retrospective study of the safety and efficacy of a first-line treatment with modified FOLFOX-4 in unresectable advanced or recurrent gastric cancer patients. Chemotherapy, 58, 411-8.
  21. Zamani N, Hajifaraji M, Fazel-tabar Malekshah A, et al (2013). A case-control study of the relationship between gastric cancer and meat consumption in Iran. Arch Iran Med, 16, 324-9.